Literature DB >> 11728947

Involvement of p38 mitogen-activated protein kinase followed by chemokine expression in crescentic glomerulonephritis.

T Wada1, K Furuichi, N Sakai, Y Hisada, K Kobayashi, N Mukaida, N Tomosugi, K Matsushima, H Yokoyama.   

Abstract

p38 Mitogen-activated protein kinase (MAPK) is involved in the production and signal transduction of interleukin-1beta (IL-1beta), tumor necrosis factor-alpha, and chemokines in vitro. However, the crucial role of p38 MAPK in the inflammatory processes of crescentic glomerulonephritis in vivo remains to be investigated. We showed a dramatic decrease in IL-1beta-induced phosphorylation of p38 MAPK, not extracellular signal-regulated kinases 1/2 or jun NH2-terminal kinase, in rat cultured mesangial cells by FR167653. We explored the effects of FR167653 as a specific inhibitor of p38 MAPK on renal injury and subsequent renal expression of chemokines in a progressive experimental crescentic glomerulonephritis model in Wistar-Kyoto rats. Rats developed crescentic glomerulonephritis leading to glomerulosclerosis and interstitial fibrosis by 56 days after the administration of nephrotoxic sera. The number of phosphorylated p38 MAPK-positive cells, detected mainly in crescents, correlated well with the percentage of crescents and number of ED-1-positive cells. Phosphorylated p38 MAPK-positive cells were downregulated in glomeruli in rats with the daily subcutaneous administration of FR167653 for 6 days. Concomitantly, renal expression of macrophage inflammatory protein-1alpha and monocyte chemoattractant protein-1/monocyte chemotactic and activating factor was markedly reduced by day 6. The severity of glomerulosclerosis and interstitial fibrosis significantly decreased by day 56, and renal function was preserved. These results suggest that p38 MAPK phosphorylation is pivotal for crescentic glomerulonephritis, followed by the subsequent expression of renal chemokines. This study provides evidence that regulation of p38 MAPK is a novel appealing therapeutic target for crescentic glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11728947     DOI: 10.1053/ajkd.2001.29206

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  Activation of p38 mitogen-activated protein kinase promotes peritoneal fibrosis by regulating fibrocytes.

Authors:  Satoshi Kokubo; Norihiko Sakai; Kengo Furuichi; Tadashi Toyama; Shinji Kitajima; Toshiya Okumura; Kouji Matsushima; Shuichi Kaneko; Takashi Wada
Journal:  Perit Dial Int       Date:  2011-06-30       Impact factor: 1.756

2.  Mycophenolic acid inhibits albumin-induced MCP-1 expression in renal tubular epithelial cells through the p38 MAPK pathway.

Authors:  Hua Shui; Ping Gao; Xiaoyun Si; Guohua Ding
Journal:  Mol Biol Rep       Date:  2009-07-04       Impact factor: 2.316

3.  Role of p38 MAP kinase pathway in a toxin-induced model of hemolytic uremic syndrome.

Authors:  Xue Jun Fu; Kazumoto Iijima; Kandai Nozu; Kiyoshi Hamahira; Ryojiro Tanaka; Tatsuya Oda; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2004-06-17       Impact factor: 3.714

4.  Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy.

Authors:  L Adhikary; F Chow; D J Nikolic-Paterson; C Stambe; J Dowling; R C Atkins; G H Tesch
Journal:  Diabetologia       Date:  2004-07-01       Impact factor: 10.122

5.  Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model.

Authors:  Diping Wang; Gina M Warner; Ping Yin; Bruce E Knudsen; Jingfei Cheng; Kim A Butters; Karen R Lien; Catherine E Gray; Vesna D Garovic; Lilach O Lerman; Stephen C Textor; Karl A Nath; Robert D Simari; Joseph P Grande
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-30

6.  Pharmacological and genetic inhibition of downstream targets of p38 MAPK in experimental nephrotic syndrome.

Authors:  Xiaojing Nie; Melinda A Chanley; Ruma Pengal; David B Thomas; Shipra Agrawal; William E Smoyer
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-29

7.  Inhibiting ERK Activation with CI-1040 Leads to Compensatory Upregulation of Alternate MAPKs and Plasminogen Activator Inhibitor-1 following Subtotal Nephrectomy with No Impact on Kidney Fibrosis.

Authors:  Faith Hannah Nutter; John L Haylor; Arif Khwaja
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

8.  ASK1 inhibitor treatment suppresses p38/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritis.

Authors:  Liv A Amos; Frank Y Ma; Greg H Tesch; John T Liles; David G Breckenridge; David J Nikolic-Paterson; Yingjie Han
Journal:  J Cell Mol Med       Date:  2018-07-11       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.